Proteasome inhibition reduces donor-specific antibody levels.

[1]  R. Colvin,et al.  Banff '05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (‘CAN’) , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  M. Stegall,et al.  The Effect of Desensitization Protocols on Human Splenic B‐Cell Populations In Vivo , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  A. Ballestrero,et al.  Proteasome inhibitor‐induced apoptosis in human monocyte‐derived dendritic cells , 2006, European journal of immunology.

[4]  Hiroshi Yasui,et al.  A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. , 2005, Cancer cell.

[5]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[6]  J. Serody,et al.  Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Adams.  The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.

[8]  M. Fishbein,et al.  Antibody‐Mediated Rejection Criteria – an Addition to the Banff ′97 Classification of Renal Allograft Rejection , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  P. Elliott,et al.  Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. , 2002, The Journal of clinical investigation.

[10]  Yulian Wu,et al.  A proteasome inhibitor effectively prevents mouse heart allograft rejection. , 2001, Transplantation.

[11]  P. Elliott,et al.  Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. , 2000, Journal of autoimmunity.

[12]  P. Elliott,et al.  Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[13]  W. Duguid,et al.  Role of proteasomes in T cell activation and proliferation. , 1998, Journal of immunology.